ASX 300

One upshot of the much-discussed market dislocation is that great companies are back at prices where they represent good value.

Marking the banks post the May 2026 reporting season

A look at Australia’s best-performing growth funds over five years, and the return drivers behind the leaders.

What happens when the next generation picks real assets over the AI hype cycle?

Tax policy no longer subsidises mediocre returns and lazy strategy and replacing them will be a positive change for smart investors

Australian shares remain 'tricky' as profit warnings continue to be issued, but in the background AI beneficiaries are making a come-back

As the big banks hit record highs, the experts reveal where they're hunting for value in ASX financials.

Seneca’s Luke Laretive explains what separates genuine 10-baggers from market hype, and why patience matters most.

As AI drives power demand, hear Jason explore the energy war, semiconductors, P.Credit, geopolitics, CCY, capital flows & where to allocate.

Australia's greatest blue chip has lost two-thirds of its value — how did the brokers get it so wrong, and could you have seen it coming?

ASX Defence vs global primes: Tech cohort at a premium, yet growth unearned; Services at a discount, despite sovereign-backed contracts.

Dispersions in valuations both locally and globally represent great opportunities for investors with the conviction to take a position.

The reset has created winners and losers. From small caps to global leaders, four experts share where they see value emerging in healthcare.

Two small & mid-cap gurus face off on fallen angels and high-flyers. Plus: Key insights from the Macquarie Conference.

Relying on the investment playbook of the 2010s may no longer cut it.

NextDC’s recent subordinated note issuance highlights a recurring challenge for credit investors: exposure to equity‑like risk without commensurate return. While the...

Julia Weng (Paradice) and Hamish FitzSimons (AllianceBernstein) diagnose ASX healthcare's brutal year and name the stocks set for recovery

Pricing tailwinds, AI infrastructure and a catch-up trade: where this small-cap investor sees opportunity now.

AI didn't kill ASX SaaS stocks – it killed the multiples investors would pay for them. That distinction could make or break your portfolio.

April was a big month for many of the most-shorted stocks on the ASX. Here's how things stand now.

Stocks, ETFs and sectors investors are watching as inflation and rate pressures return.

AI adoption is moving from experimentation to production, with the fastest phase of growth likely still ahead.

Gold miners are ploughing their record free cash flow into copper acquisition, in an effort to pivot.

Does "sell in May" still hold? Plus, broker calls on stocks including RMD, FMG and BOE.